Skip to main content

Table 5 Correlations of hTERT rs2736100 polymorphism with baseline characteristics of patients in the recurrence and non-recurrence groups

From: The correlations between DNA methylation and polymorphisms in the promoter region of the human telomerase reverse transcriptase (hTERT) gene with postoperative recurrence in patients with thyroid carcinoma (TC)

Characteristic

Non-recurrence group

Recurrence group

TT + TG (%)

GG (%)

P

TT + TG (%)

GG (%)

P

187

50

46

29

Tumor size

 <20 mm

127 (67.9)

30 (60.0)

0.293

31 (67.4)

16 (55.2)

0.287

 ≥20 mm

60 (32.1)

20 (40.0)

 

15 (32.6)

13 (44.8)

Multicentricity

 Yes

115 (61.5)

28 (56.0)

0.532

27 (58.7)

9 (31.0)

0.02

 No

72 (38.5)

14 (28.0)

 

19 (41.3)

20 (69.0)

Extrathyroidal invasion

 Yes

66 (35.3)

22 (44.0)

0.258

11 (23.9)

22 (75.9)

<0.001

 No

121 (64.7)

28 (56.0)

 

35 (76.1)

7 (24.1)

Lymph node metastasis

 Yes

33 (17.6)

11 (22.0)

0.482

25 (54.3)

23 (79.3)

0.028

 No

154 (82.4)

39 (78.0)

 

21 (45.7)

6 (20.7)

Pathological type

 Papillary thyroid carcinoma

173 (92.5)

47 (94.0)

0.907

27 (58.7)

10 (34.5)

0.004

 Follicular thyroid carcinoma

8 (4.3)

2 (4.0)

 

5 (10.9)

2 (6.9)

 Medullary thyroid carcinoma

4 (2.1)

1 (2.0)

 

8 (17.4)

2 (6.9)

 Undifferentiated carcinoma

2 (1.1)

0

 

6 (13.0)

15 (51.7)

Tumor stage

 I + II

156 (83.4)

43 (86.0)

0.659

21 (45.7)

9 (31.0)

 

 III + IV

31 (16.6)

7 (14.0)

 

25 (54.3)

20 (69.0)

0.208

  1. hTERT human telomerase reverse transcriptase